SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ---------------------------------- Date of Report (DATE OF EARLIEST EVENT REPORTED): JANUARY 28, 2003 ANIKA THERAPEUTICS, INC. -------------------------------------------------------------------------------- (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER) MASSACHUSETTS 000-21326 04-3145961 ------------------------------- ----------------------- ---------------------- (STATE OR OTHER JURISDICTION (COMMISSION FILE (IRS EMPLOYER OF INCORPORATION) NUMBER) IDENTIFICATION NO.) 160 NEW BOSTON STREET, WOBURN, MASSACHUSETTS 01801 -------------------------------------------------------------------------------- (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE) (781) 932-6616 -------------------------------------------------------------------------------- (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE) ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) EXHIBITS Exhibit 99.1--Press Release of Anika Therapeutics, Inc. dated January 28, 2003 ITEM 9. REGULATION FD DISCLOSURE. On January 28, 2003 Anika Therapeutics, Inc. issued the press release attached hereto as Exhibit 99.1 and incorporated herein in its entirety. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANIKA THERAPEUTICS, INC. Date: January 30, 2003 /s/ CHARLES H. SHERWOOD -------------------------------------- Charles H. Sherwood Chief Executive Officer and President EXHIBIT INDEX EXHIBIT NO. DESCRIPTION ----------- ----------- 99.1 Press Release of Anika Therapeutics, Inc. dated January 28, 2003